表紙
市場調査レポート

アジア太平洋地域の幹細胞治療市場:好ましい政府の政策、強力なパイプライン、ライセンス活動の活発化による商業化の支援

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

発行 GBI Research 商品コード 257410
出版日 ページ情報 英文 112 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
アジア太平洋地域の幹細胞治療市場:好ましい政府の政策、強力なパイプライン、ライセンス活動の活発化による商業化の支援 Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity
出版日: 2012年12月14日 ページ情報: 英文 112 Pages
概要

アジア太平洋地域の幹細胞治療市場は、2012年には5億4500万米ドル、2018年には9億7200万米ドルの規模に達し、その間の年平均(CAGR)市場成長率は約10%となると予想されています。各国での新規の治療薬の発売開始が、市場の成長を促進するものと思われます。

当レポートでは、アジア太平洋地域諸国における幹細胞治療市場について分析し、全体的な市場の特徴・傾向や、各国市場の詳細動向や規制環境、各国における個別製品の動向、主要企業のプロファイル(企業器用・製品パイプライン)、資本取引の最新状況などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
  • 市場の特徴と予測:概要
    • 収益予測
    • 治療費
    • 同種幹細胞/自己幹細胞治療のシェア
  • 市場促進・阻害要因
    • 市場促進要因
    • 市場阻害要因

第4章 インド

  • イントロダクション
  • 規制環境
  • 市場の特徴と予測:概要
  • 冠動脈バイパスグラフト(CABG)市場の特徴と予測
  • 第二種糖尿病(DM)市場の特徴と予測
  • 角膜輪部幹細胞技術(LSCT)市場の特徴と予測

第5章 中国

  • イントロダクション
  • 規制環境
  • 市場の特徴と予測:概要
    • 第一種糖尿病市場の特徴と予測

第6章 日本

  • イントロダクション
  • 規制環境
  • ステロイド抵抗性aGvHD市場の特徴と予測

第7章 シンガポール

  • イントロダクション
  • 規制環境:過去の倫理的・法的問題(全7件)

第8章 韓国

  • イントロダクション
  • 規制環境
  • 市場の特徴と予測:概要
  • Cupistemの市場の特徴と予測
  • HCG-AMIの市場の特徴と予測
  • Cartistemの市場の特徴と予測
  • CCGの市場の特徴と予測

第9章 パイプライン分析

  • フェーズ(相)別のパイプライン分析
  • スポンサー/共同開発企業別のパイプライン分析
  • 国別のパイプライン分析

第10章 競争環境

  • Stempeutics Research
  • Reliance Life Sciences
  • International Stem Cell Services
  • Shenzhen Beike Biotechnology
  • JCR Pharmaceuticals
  • ES Cells International(BioTime, Incの子会社)
  • Stem Cell Technologies I
  • Pharmicell
  • Medipost

第11章 戦略的な業界再編

  • 概要
  • 企業合併・買収(M&A)取引(全3件)
  • ライセンス取引(全7件)
  • 共同開発取引(全4件)

第12章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC274MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity". The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals' JR-031 (2014) in Japan and FCB Pharmicell's Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Scope

  • Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore
  • In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers.
  • Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem.
  • Key drivers and restraints that have a significant impact on the market.
  • Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost
  • Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.

Reasons to buy

  • Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
  • Develop key strategic initiatives by studying the key strategies of top competitors
  • Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety

Executive Summary

Stem Cell Research in Asia-Pacific a "Growth Engine" for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a "new growth engine" for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

This report provides an in-depth analysis on stem cell research and development in India, China, Japan, South Korea and Singapore. Market analysis and forecasts are given for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines, and covers market drivers and challenges for the stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Stem Cell Therapy Market in Asia-Pacific to 2018-Introduction

3. Stem Cell Therapy Market in Asia-Pacific to 2018-Overview

  • 3.1. Introduction
  • 3.2. Market Characterization and Forecasts-Overview
    • 3.2.1. Revenue Forecasts
    • 3.2.2. Cost of Therapy
    • 3.2.3. Allogeneic and Autologous Share
    • 3.2.4. Stem Cell Therapy Patient Pool
  • 3.3. Drivers and Barriers
    • 3.3.1. Drivers
    • 3.3.2. Barriers

4. Stem Cell Therapy Market in Asia-Pacific to 2018-India

  • 4.1. Introduction
  • 4.2. Regulatory Landscape
  • 4.3. Market Characterization and Forecasts-Overview
    • 4.3.1. Revenue Forecasts
    • 4.3.2. Cost of Therapy
    • 4.3.3. Stem Cell Patient Pool
  • 4.4. CABG Market Characterization and Forecasts
    • 4.4.1. Introduction
    • 4.4.2. Revenue Forecasts
    • 4.4.3. Cost of Therapy
    • 4.4.4. Stem Cell Patient Pool
  • 4.5. Type 2 DM Market Characterization and Forecasts
    • 4.5.1. Introduction
    • 4.5.2. Revenue Forecasts
    • 4.5.3. Cost of Therapy
    • 4.5.4. Stem Cell Patient Pool
  • 4.6. LSCT Market Characterization and Forecasts
    • 4.6.1. Introduction
    • 4.6.2. Revenue Forecasts
    • 4.6.3. Cost of Therapy
    • 4.6.4. Stem Cell Patient Pool

5. Stem Cell Therapy Market in Asia-Pacific to 2018-China

  • 5.1. Introduction
  • 5.2. Regulatory Landscape
  • 5.3. Market Characterization and Forecasts-Overview
    • 5.3.1. Type 1 DM Market Characterization and Forecasts

6. Stem Cell Therapy Market in Asia-Pacific to 2018-Japan

  • 6.1. Introduction
  • 6.2. Regulatory Landscape
  • 6.3. Steroid Refractory aGvHD Market Characterization and Forecasts
    • 6.3.1. Overview
    • 6.3.2. Revenue Forecasts
    • 6.3.3. Cost of Therapy
    • 6.3.4. Stem Cell Patient Pool

7. Stem Cell Therapy Market in Asia-Pacific to 2018-Singapore

  • 7.1. Introduction
  • 7.2. Regulatory Landscape
    • 7.2.1. Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002)
    • 7.2.2. Human Tissue Research (November 2002)
    • 7.2.3. Research Involving Human Subjects (November 2004)
    • 7.2.4. Genetic Testing and Genetic Research (November 2005)
    • 7.2.5. Personal Information in Biomedical Research (May 2007)
    • 7.2.6. Donation of Human Eggs for Research (November 2008)
    • 7.2.7. Human-Animal Combinations in Stem Cell Research (September 2010)

8. Stem Cell Therapy Market in Asia-Pacific to 2018-South Korea

  • 8.1. Introduction
  • 8.2. Regulatory Landscape
  • 8.3. Market Characterization and Forecasts-Overview
    • 8.3.1. Revenue Forecasts
    • 8.3.2. Cost of Therapy
    • 8.3.3. Stem Cell Patient Pool
  • 8.4. Cupistem Market Characterization and Forecasts
    • 8.4.1. Overview
    • 8.4.2. Revenue Forecasts
    • 8.4.3. Cost of Therapy
    • 8.4.4. Stem Cell Patient Pool
  • 8.5. HCG-AMI Market Characterization and Forecasts
    • 8.5.1. Overview
    • 8.5.2. Revenue Forecasts
    • 8.5.3. Cost of Therapy
    • 8.5.4. Stem Cell Patient Pool
  • 8.6. Cartistem Market Characterization and Forecasts
    • 8.6.1. Overview
    • 8.6.2. Revenue Forecasts
    • 8.6.3. Cost of Therapy
    • 8.6.4. Stem Cell Patient Pool
  • 8.7. CCG Market Characterization and Forecasts
    • 8.7.1. Overview
    • 8.7.2. Revenue Forecasts
    • 8.7.3. Cost of Therapy
    • 8.7.4. Stem Cell Patient Pool

9. Stem Cell Therapy Market in Asia-Pacific to 2018-Pipeline Analysis

  • 9.1. Pipeline Analysis by Phase
  • 9.2. Pipeline Analysis by Sponsors/Collaborators
  • 9.3. Pipeline Analysis by Country
    • 9.3.1. India Stem Cell R&D Pipeline
    • 9.3.2. China Stem Cell R&D Pipeline
    • 9.3.3. Japan Stem Cell R&D Pipeline
    • 9.3.4. Singapore Stem Cell R&D Pipeline
    • 9.3.5. South Korea Stem Cell R&D Pipeline
    • 9.3.6. Product Profiles of Promising Molecules
    • 9.3.7. Product Profiles of Marketed Products

10. Stem Cell Therapy Market in Asia-Pacific to 2018-Competitive Landscape

  • 10.1. Stempeutics Research
    • 10.1.1. Overview
    • 10.1.2. Product Pipeline
  • 10.2. Reliance Life Sciences
    • 10.2.1. Overview
    • 10.2.2. Product Pipeline
  • 10.3. International Stem Cell Services
    • 10.3.1. Overview
    • 10.3.2. Product Pipeline
  • 10.4. Shenzhen Beike Biotechnology
    • 10.4.1. Overview
    • 10.4.2. Product Pipeline
  • 10.5. JCR Pharmaceuticals
    • 10.5.1. Overview
    • 10.5.2. Product Pipeline
  • 10.6. ES Cells International (Subsidiary of BioTime, Inc)
    • 10.6.1. Overview
    • 10.6.2. Product Pipeline
  • 10.7. Stem Cell Technologies I
    • 10.7.1. Overview
    • 10.7.2. Product Pipeline
  • 10.8. Pharmicell
    • 10.8.1. Overview
    • 10.8.2. Product Pipeline
  • 10.9. Medipost
    • 10.9.1. Overview
    • 10.9.2. Product Pipeline

11. Stem Cell Therapy Market in Asia-Pacific to 2018-Strategic Consolidations

  • 11.1. Overview
  • 11.2. M&A Deals
    • 11.2.1. RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m-October 28, 2011
    • 11.2.2. BioTime Acquired ES Cell International-May 3, 2010
    • 11.2.3. BCCL Acquires Stake in Life Cell-May 1, 2007
  • 11.3. Licensing Deals
    • 11.3.1. RNL BIO Forms Joint Venture to Develop Stem Cell Therapy-September 29, 2011
    • 11.3.2. Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR-January 4, 2011
    • 11.3.3. Cipla Enters into Co-Marketing Agreement with Stempeutics-April 27, 2010
    • 11.3.4. Teijin Enters into Licensing Agreement with SanBio-March 2, 2010
    • 11.3.5. Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma-September 9, 2009
    • 11.3.6. Merck Signs a Licensing Agreement with Japan Tobacco-September 25, 2008
    • 11.3.7. ES Cell Enters into Licensing Agreement with ITI Life Sciences-January 31, 2007
  • 11.4. Co-Development Deals
    • 11.4.1. JCR Pharma Enters into Co-Development Agreement with MediPal-September 13, 2011
    • 11.4.2. Athersys Enters into Co-Development Agreement with Pfizer-December 21, 2009
    • 11.4.3. Genzyme Enters into Agreement with Osiris Therapeutics-November 4, 2008
    • 11.4.4. JCR Pharma Enters into Co-Development Agreement with Mochida Pharma-December 21, 2007

12. Stem Cell Therapy Market in Asia-Pacific to 2018-Appendix

  • 12.1. Market Definitions
  • 12.2. Abbreviations
  • 12.3. Bibliography
  • 12.4. Research Methodology
    • 12.4.1. Coverage
    • 12.4.2. Secondary Research
    • 12.4.3. Primary Research
  • 12.5. Therapeutic Landscape
    • 12.5.2. Market Size by Geography
  • 12.6. Geographical Landscape
  • 12.7. Pipeline Analysis
  • 12.8. Competitive Landscape
    • 12.8.1. Expert Panel Validation
  • 12.9. Contact Us
  • 12.10. Disclaimer

List of Tables

  • Table 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018
  • Table 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts ('000), 2012-2018
  • Table 3: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018
  • Table 4: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts ('000), 2012-2018
  • Table 5: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($'000), 2012-2018
  • Table 6: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018
  • Table 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018
  • Table 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018
  • Table 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018
  • Table 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts ('000), 2012-2018
  • Table 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($'000), 2012-2018
  • Table 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018
  • Table 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018
  • Table 14: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018
  • Table 15: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018
  • Table 16: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts ('000), 2012-2018
  • Table 17: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018
  • Table 18: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018
  • Table 19: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018
  • Table 20: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018
  • Table 21: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018
  • Table 22: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018
  • Table 23: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018
  • Table 24: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018
  • Table 25: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018
  • Table 26: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018
  • Table 27: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts, 2012-2018
  • Table 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018
  • Table 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018
  • Table 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018
  • Table 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018
  • Table 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018
  • Table 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018
  • Table 34: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase, 2012
  • Table 35: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators, 2012
  • Table 36: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country, 2012
  • Table 37: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase, 2012
  • Table 38: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II/III Pipeline Analysis, 2012
  • Table 39: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II Pipeline Analysis, 2012
  • Table 40: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase I/II Pipeline Analysis, 2012
  • Table 41: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Unknown Phase, 2012
  • Table 42: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase, 2012
  • Table 43: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Post-Market Pipeline Analysis, 2012
  • Table 44: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase II Pipeline Analysis, 2012
  • Table 45: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I/II Pipeline Analysis, 2012
  • Table 46: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I Pipeline Analysis, 2012
  • Table 47: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Clinical Pre-Test Pipeline Analysis, 2012
  • Table 48: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Unknown Phase, 2012
  • Table 49: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase, 2012
  • Table 50: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase III Stage Molecules Pipeline Analysis, 2012
  • Table 51: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II/III Stage Molecules Pipeline Analysis, 2012
  • Table 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II Stage Molecules Pipeline Analysis, 2012
  • Table 53: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I/II Stage Molecules Pipeline Analysis, 2012
  • Table 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I Stage Molecules Pipeline Analysis, 2012
  • Table 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Singapore, Phase I/II Stage Molecules Pipeline Analysis, 2012
  • Table 56: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase, 2012
  • Table 57: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase III Molecules Pipeline Analysis, 2012
  • Table 58: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II/III Molecules Pipeline Analysis, 2012
  • Table 59: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II Molecules Pipeline Analysis, 2012
  • Table 60: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I/II Molecules Pipeline Analysis, 2012
  • Table 61: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I Molecules Pipeline Analysis, 2012
  • Table 62: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Unknown Phase, 2012
  • Table 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, R&D Pipeline, 2012
  • Table 64: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, R&D Pipeline, 2012
  • Table 65: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services Limited, R&D Pipeline, 2012
  • Table 66: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology R&D Pipeline, 2012
  • Table 67: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Co. Ltd, R&D Pipeline, 2012
  • Table 68: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell, R&D Pipeline, 2012
  • Table 69: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, R&D Pipeline, 2012
  • Table 70: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview, 2007-2012

List of Figures

  • Figure 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Overview, 2012
  • Figure 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018
  • Figure 3: Stem Cell Therapy Market in Asia-Pacific to 2018, Cost of Therapy Overview ($), 2012
  • Figure 4: Stem Cell Therapy Market in Asia-Pacific to 2018, Allogeneic vs. Autologous (%), 2012
  • Figure 5: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts ('000), 2012-2018
  • Figure 6: Stem Cell Therapy Market in Asia-Pacific to 2018, Drivers and Barriers, 2012
  • Figure 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018
  • Figure 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Cost of Therapy Overview ($), 2012
  • Figure 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts ('000), 2012-2018
  • Figure 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($'000), 2012-2018
  • Figure 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018
  • Figure 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018
  • Figure 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018
  • Figure 14: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018
  • Figure 15: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts ('000), 2012-2018
  • Figure 16: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($'000), 2012-2018
  • Figure 17: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018
  • Figure 18: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018
  • Figure 19: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Regulatory Framework Timeline, 1998-2009
  • Figure 20: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018
  • Figure 21: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018
  • Figure 22: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts ('000), 2012-2018
  • Figure 23: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, MHLW Stem Cell Guidelines, 2010
  • Figure 24: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, JR-031 Overview, 2012
  • Figure 25: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018
  • Figure 26: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018
  • Figure 27: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018
  • Figure 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Stem Cell Therapeutics Approval Process, 2011
  • Figure 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Biopharmaceutical Implementation Strategies, 2011
  • Figure 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018
  • Figure 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Autologous and Allogeneic Share (%), 2012
  • Figure 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Marketed Products Share (%), 2012 and 2018
  • Figure 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cost of Therapy ($), Overview, 2012
  • Figure 34: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018
  • Figure 35: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018
  • Figure 36: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018
  • Figure 37: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018
  • Figure 38: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018
  • Figure 39: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018
  • Figure 40: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts (Absolute), 2012-2018
  • Figure 41: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018
  • Figure 42: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018
  • Figure 43: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018
  • Figure 44: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018
  • Figure 45: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018
  • Figure 46: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018
  • Figure 47: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase (%), 2012
  • Figure 48: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators (%), 2012
  • Figure 49: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country (%), 2012
  • Figure 50: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase (%), 2012
  • Figure 51: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase (%), 2012
  • Figure 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase (%), 2012
  • Figure 53: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase (%), 2012
  • Figure 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, Overview, 2012
  • Figure 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, Overview, 2012
  • Figure 56: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services, Overview, 2012
  • Figure 57: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology Overview, 2012
  • Figure 58: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Overview, 2012
  • Figure 59: Stem Cell Therapy Market in Asia-Pacific to 2018, ES Cells International, Overview, 2012
  • Figure 60: Stem Cell Therapy Market in Asia-Pacific to 2018, Stem Cell Technologies I, Overview, 2012
  • Figure 61: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell Overview, 2012
  • Figure 62: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, Overview, 2012
  • Figure 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview (%), 2007-2012
  • Figure 64: GBI Research Market Forecasting Model
Back to Top